启德医药科技（苏州）有限公司 Kai Tak Pharmaceutical Technology (Suzhou) Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
GeneQuantum and BioMap establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics 2023-12-18 09:43
GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development 2023-07-17 17:00
Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs 2023-07-07 10:19
GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development 2022-12-26 23:01
GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia 2022-05-16 09:00
GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate 2022-04-19 09:00
GeneQuantum announces two key leadership appointments 2021-09-16 09:00
GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates 2021-09-06 09:00
GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science 2021-08-30 10:00
GeneQuantum announces a key leadership appointment 2021-08-16 10:00
GeneQuantum Raises Hundreds of Millions RMB in Series C Funding 2021-05-19 10:30
World's first iLDC enabling ADC drug receives IND clearance by the US FDA 2020-06-11 17:10
GeneQuantum Healthcare completed nearly RMB 100 million in Pre-B financing 2019-05-08 08:00
GeneQuantum Healthcare and MITRO Biotech Enter into Strategic Cooperation to Develop Next Generation Radionuclide Conjugates 2019-02-03 20:00
Strategic Cooperation between GeneQuantum Healthcare and Biocytogen on Development of Antitumor Bioconjugates 2018-11-01 10:00
1